common.study.topics.clinical

Treatment of Breast Cancer

common.study.values.description

Copper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer

This phase II trial studies how well copper Cu64-DOTA-trastuzumab positron emission tomography (PET) works in predicting response to treatment with trastuzumab and pertuzumab before surgery in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread from where it started to nearby tissue or lymph nodes. Diagnostic procedures, such as copper Cu 64 DOTA-trastuzumab PET, may help predict a patient's response to trastuzumab and pertuzumab before surgery in patients with locally advanced HER2 positive breast cancer.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Radiation - Copper Cu 64-DOTA-Trastuzumab

Given IV

Laboratory Biomarker Analysis

Correlative studies

Biological - Pertuzumab

Given IV

Procedure - Positron Emission Tomography

Undergo PET

Procedure - Therapeutic Conventional Surgery

Undergo surgery

Biological - Trastuzumab

Given IV

participant.views.study.view.additional

participant.views.study.view.scientific-title

Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzumab-Based Neoadjuvant Therapy

common.study.values.clinical-trial-id

NCT02827877

participant.views.study.view.id

ZdPGAb